ZERIT XR
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASE
Approved
Dec 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZERIT XR is an extended-release oral capsule small-molecule approved by FDA in 2002. The specific indication and mechanism of action are not documented in available data. This product represents a sustained-release formulation approach to improve patient compliance.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), signaling a mature team focused on retention and lifecycle management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and an LOE-approaching lifecycle, career opportunities on ZERIT XR are limited and oriented toward defensive commercial roles rather than growth or launch positions. This assignment offers experience in mature product management and generic competition strategy but limited upside visibility.
Brand ManagerField Sales
Worked on ZERIT XR at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.